Search Results

17 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 45

    Meta-analysis of two biomarkers of exposure of tobacco products

    AYALA-FIERRO F.(1); ELAMIN A.(2); FROST-PINEDA K.(3); JIN T.(3); PRASAD G.L.(3); SARKAR M.(4); SCHMIDT E.(3); VERRON T.(5)
    (1) ITG Brands LLC, Greensboro, NC, U.S.A.; (2) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (3) RAI Services Company, Winston-Salem, NC, U.S.A.; (4) Altria Client Services LLC, Richmond, VA, U.S.A.; (5) SEITA - Imperial Brands, Paris, France
    In the context of tobacco products, broadly two types of biomarkers exist, biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH). BoE measure exposure to tobacco constituents, e.g. carbon monoxide (CO) and nicotine equivalents (NEQs)....
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 33

    Quantitative risk assessment (QRA) indicates reduced risk potential for carcinogenic and non-carcinogenic effects of the aerosol of the next generation products (NGPs) compared to reference cigarettes

    AYALA-FIERRO F.(1); CZEKALA L.(2); SIMMS L.(2); RUDD K.(2); CAVA G.(2); STEVENSON M.(2)
    (1) ITG Brands LLC, Greensboro, NC, U.S.A.; (2) Imperial Brands PLC, Bristol, U.K.
    In order to understand the potential relative health risks of NGPs compared to cigarettes, we compared the relative risks of aerosols from tobacco-containing and tobacco-free NGPs to the smoke generated from a reference cigarette. Quantitative Risk...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 58

    A consortium approach for consumer-reported outcome measures to assess tobacco- and nicotine-containing products

    ACQUADRO C.(1) on behalf of the CORESTA CROM Task Force: AYALA-FIERRO F.(2); BLACK R.(3); CAHOURS X.(4); CHREA C.(5); CURTIN G.(6); GILES L.(7); McCAFFREY S.(3); PARK C.H.(8); PRASAD K.(9); SHERWOOD N.(10); SHIFFMAN S.(11); SMITH J.(6); SPIES E.(5)
    (1) Mapi Research Trust, Lyon, France; (2) ITG Brands, Greensboro, NC, U.S.A.; (3) Altria Client Services, Richmond, VA, U.S.A.; (4) SEITA - Imperial Brands, Paris, France; (5) Philip Morris Products S.A., Neûchatel, Switzerland; (6) RAIS, Winston-Salem, NC, U.S.A.; (7) JT Int'l SA, Genève, Switzerland; (8) KT&G Research Institute, Daejeon, Republic of Korea; (9) British American Tobacco, Southampton, U.K.; (10) Neil Sherwood Consulting, Commugny, Switzerland; (11) Pinney Associates, Pittsburgh, PA, U.S.A.
    In the tobacco space, consumer-reported outcome measures (CROM) are essential for understanding motivations, subjective effects, and behavior. Such measures have become particularly important with the advent of candidate modified risk tobacco...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 03

    Comparison of select analytes in tobacco and smoke for cigar products across a range of design features

    TAYYARAH R.; ZHU J.; BROOKS C.; STEVENS R.
    ITG Brands LLC, Greensboro, NC, U.S.A.
    On August 8, 2016, the FDA finalized a rule that extended its regulatory authority to all tobacco products, including e-cigarettes, cigars, and hookah and pipe tobacco, as part of its goal to improve public health. While the analytical testing of...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 04

    Challenges and considerations for methods development and testing of cigar products for smoke constituents beyond TNCO

    TAYYARAH R.; STEVENS R.; ZHU J.; BROOKS C.
    ITG Brands LLC, Greensboro, NC, U.S.A.
    While testing for smoke constituents for conventional cigarettes is challenging, there is a rich body of literature, inter-laboratory studies, and significant hands-on experience for this area of work. On the other hand experience and standardization...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 29 (also presented at TSRC 2017)

    Impact of cigar physical variability on cigar exposure using probabilistic risk assessment

    AYALA-FIERRO F.; KOSARAJU K.; STEVENS R.
    ITG Brands LLC, Greensboro, NC, U.S.A.
    Cigars are unique tobacco products of wide variety of sizes: length, diameter and weight, and include large cigars, small cigars (cigarette-like) and cigarillos. The weight of cigars can range widely which influences exposure to cigar constituents,...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 30 (also presented at TSRC 2017)

    Comparison of probability of risk associated with cigar exposure

    KOSARAJU K.; AYALA-FIERRO F.; STEVENS R.
    ITG Brands LLC, Greensboro, NC, U.S.A.
    Cigars are unique tobacco products of variable physical and chemical properties. Limited information is available about exposure to smoke and probability of risk, if any, to smoke constituents. Cigar smokers can be exclusive or dual smokers of cigars...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 62

    Overview of in vitro methods used to assess e-cigarettes based on “Toxicity Testing in 21st Century” principles

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); WALELE T.(2)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    When the National Academies of Sciences released “Toxicity Testing in the 21st Century: A Vision and a Strategy” a new toxicological paradigm was created, focusing on the use of human cell lines and the disruption of key cellular pathways. In keeping...
  9. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 08

    Indoor air quality and surface deposition assessment following use of an open system e-cigarette

    BAUER N.(1); TSCHIERSKE N.(1); O'CONNELL G.(2); CAHOURS X.(3)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (2) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands; (3) SEITA-Imperial Tobacco Limited, Fleury-les-Aubrais, France
    Electronic cigarette (e-cigarette) nicotine delivery devices are growing in popularity worldwide. Both regulators and public health organisations are beginning to examine potential implications that exposure to exhaled e-cigarette aerosol may have on...
  10. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 21

    The use of in vitro human biomarkers from relevant primary cell lines, to assess the effects of increasing nicotine concentration in e-liquids

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); BERG E.(2); WALELE T.(3)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) DiscoverX Corporation, Fremont, CA, U.S.A.; (3) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    As part of the ongoing stewardship of electronic cigarettes, and in line with the National Academies of Sciences “Toxicity Testing in the 21st Century: A Vision and a Strategy”, Fontem Ventures B.V. have investigated the utility of a series of...